Randomized trial of high-flux vs low-flux haemodialysis: Effects on homocysteine and lipids

Nephrology Dialysis Transplantation

Volumn 15, Issue 7, 2000, Pages 1029-1034

  House, Andrew A ^a   Wells, George A ^b   Donnelly, James G ^c   Nadler, Steven P ^c   Hébert, Paul C ^b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Haemodialysis; Homocysteine; Polysulphone; Prospective studies

Indexed keywords

HOMOCYSTEINE; LIPID; LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034131235     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.7.1029     Document Type: Article

References (25)

1. US Renal Data System, USRDS 1997 Annual Data Report. Table D.4. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1997
2. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141
3. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554-2558
4. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-482
5. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91-101
6. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103
7. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49: 1360-1371
8. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
9. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703-1708
10. Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C. Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients. Nephron 1995; 69: 323-326
11. Chauveau P, Chadefaux B, Coudé M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41: S72-77
12. de Précigout V, Higueret D, Larroumet N et al. Improvement in lipid profiles and triglyceride removal in patients on polyamide membrane hemodialysis. Blood Purif 1996; 14: 170-176
13. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3: 1409-1415
14. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 20: 361-366
15. Dellana F, Kissinger GL, Baldamus CA. Hyperhomocysteinemia in dialysis patients and homocystein clearances of different hemodialyzers. J Am Soc Nephrol 1997; 8: 232A (Abstract)
16. Kissinger GL, Dellana F, Baldamus CA. Hyperhomocysteinemia in dialysis patients: effects of a folic acid treatment and different dialysis membranes over 6 months. J Am Soc Nephrol 1997; 8: 241A (Abstract)
17. House AA, Wells GA, Donnelly JG, Nadler SP, Hébert PC. Effect of high flux vs low flux hemodialysis on homocysteine, lipoprotein(a) and lipid profiles: A prospective, randomized trial. J Am Soc Nephrol 1998; 9: 211A (Abstract)
18. Donnelly JG, Livesey JF, Ooi DS. An HPLC method for quantitation of serum (plasma) homocysteine. Clin Chem 1997; 43: S168 (Abstract)
19. Födinger M, Mannhalter C, Wölfl G et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523
20. Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996; 120: 241-244
21. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142-146
22. Floridi A, Buoncristiani U, Fagugli RM, Cantelmi MG, Covarelli C. Daily hemodialysis (DHD) effectively lowers hyperhomocysteinemia in uremic patients. J Am Soc Nephrol 1998; 9: 233A (Abstract)
23. Arnadottir M, Brattström L, Simonsen O et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-240
24. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236
25. Ingram AJ, Parbtani A, Churchill DN. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins - a cross-over trial. Nephrol Dial Transplant 1998; 13: 1452-1457